SI-BONE Beheer

Beheer criteriumcontroles 3/4

De CEO SI-BONE is Laura Francis, benoemd in Apr2021, heeft een ambtstermijn van 3.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.71M, bestaande uit 16.8% salaris en 83.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.84% van de aandelen van het bedrijf, ter waarde € 4.27M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.6 jaar en 13.9 jaar.

Belangrijke informatie

Laura Francis

Algemeen directeur

US$3.7m

Totale compensatie

Percentage CEO-salaris	16.8%
Dienstverband CEO	3.6yrs
Eigendom CEO	0.8%
Management gemiddelde ambtstermijn	3.6yrs
Gemiddelde ambtstermijn bestuur	13.9yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Laura Francis's beloning veranderd ten opzichte van SI-BONE's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$37m
Jun 30 2024	n/a	n/a	-US$41m
Mar 31 2024	n/a	n/a	-US$43m
Dec 31 2023	US$4m	US$622k	-US$43m
Sep 30 2023	n/a	n/a	-US$44m
Jun 30 2023	n/a	n/a	-US$48m
Mar 31 2023	n/a	n/a	-US$55m
Dec 31 2022	US$5m	US$604k	-US$61m
Sep 30 2022	n/a	n/a	-US$65m
Jun 30 2022	n/a	n/a	-US$66m
Mar 31 2022	n/a	n/a	-US$62m
Dec 31 2021	US$3m	US$527k	-US$57m
Sep 30 2021	n/a	n/a	-US$51m
Jun 30 2021	n/a	n/a	-US$45m
Mar 31 2021	n/a	n/a	-US$43m
Dec 31 2020	US$2m	US$386k	-US$44m
Sep 30 2020	n/a	n/a	-US$44m
Jun 30 2020	n/a	n/a	-US$46m
Mar 31 2020	n/a	n/a	-US$42m
Dec 31 2019	US$2m	US$375k	-US$38m
Sep 30 2019	n/a	n/a	-US$35m
Jun 30 2019	n/a	n/a	-US$28m
Mar 31 2019	n/a	n/a	-US$23m
Dec 31 2018	US$734k	US$319k	-US$17m
Sep 30 2018	n/a	n/a	-US$17m
Jun 30 2018	n/a	n/a	-US$18m
Mar 31 2018	n/a	n/a	-US$21m
Dec 31 2017	US$518k	US$302k	-US$23m

Compensatie versus markt: De totale vergoeding ($USD 3.71M ) Laura } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.03M ).

Compensatie versus inkomsten: De vergoeding van Laura is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Laura Francis (57 yo)

3.6yrs

Tenure

US$3,713,871

Compensatie

Ms. Laura A. Francis, MBA, serves as Chief Executive Officer and Director at SI-BONE, Inc. since April 18, 2021. She was Chief Financial Officer of SI-Bone Inc. since May 26, 2015 until April 18, 2021 and...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Laura Francis	CEO & Director	3.6yrs	US$3.71m	0.84% € 4.3m
Anshul Maheshwari	Chief Financial Officer	3.6yrs	US$1.86m	0.17% € 846.8k
Anthony Recupero	President of Commercial Operations	8.3yrs	US$2.06m	0.23% € 1.2m
Jeff Bertolini	Senior Vice President of Operations & Information Technology	2.3yrs	geen gegevens	geen gegevens
Scott Yerby	Senior VP of Engineering & CTO	no data	geen gegevens	geen gegevens
Saqib Iqbal	Director of FP&A and Investor Relations	no data	geen gegevens	geen gegevens
Michael Pisetsky	Chief Business & Legal Affairs Officer	8.3yrs	geen gegevens	geen gegevens
Aimee Einstein	Vice President of People & Culture	2.8yrs	geen gegevens	geen gegevens
Daniel Cher	Senior Vice President of Clinical & Regulatory Affairs	3.4yrs	geen gegevens	geen gegevens
W. Reckling	Chief Medical Officer & VP of Medical Affairs	no data	geen gegevens	geen gegevens
Nikolas Kerr	Senior Vice President of Product	3.6yrs	geen gegevens	geen gegevens
Troy Wahlenmaier	Senior Vice President of US Sales	less than a year	geen gegevens	geen gegevens

3.6yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 2K3 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Laura Francis	CEO & Director	3.6yrs	US$3.71m	0.84% € 4.3m
Timothy Davis	Lead Independent Director	16.6yrs	US$211.30k	0.092% € 465.6k
Gregory Hinckley	Independent Director	13.8yrs	US$191.30k	0.38% € 1.9m
Jeryl Hilleman	Independent Director	4.9yrs	US$206.30k	0.025% € 126.5k
John Freund	Independent Director	11.8yrs	US$188.30k	0.31% € 1.6m
Ralph Rashbaum	Member of Medical Advisory Board	14.8yrs	geen gegevens	geen gegevens
Steven Garfin	Member of Medical Advisory Board	14.8yrs	geen gegevens	geen gegevens
Frank Phillips	Member of Medical Advisory Board	14.8yrs	geen gegevens	geen gegevens
Jeffrey Dunn	Executive Chairman	16.6yrs	US$551.18k	0.26% € 1.3m
A. Shamie	Member of Medical Advisory Board	13.9yrs	geen gegevens	geen gegevens
Mika Nishimura	Independent Director	3.7yrs	US$188.30k	0.046% € 233.4k
Jonathan Hyde	Member of Surgeon Advisory Board	no data	geen gegevens	geen gegevens

13.9yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 2K3 zijn ervaren en ervaren (gemiddelde ambtstermijn van 13.9 jaar).

SI-BONE Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

CEO & Director recently sold €126k worth of stock

Insufficient new directors

SI-BONE, Inc., Annual General Meeting, Jun 25, 2024

CEO & Director recently sold €751k worth of stock

Executive Chairman recently sold €130k worth of stock

CEO & Director recently sold €173k worth of stock

Recent updates

Third quarter 2024 earnings released: US$0.16 loss per share (vs US$0.25 loss in 3Q 2023)

SI-BONE, Inc. Updates Financial Guidance for the Year 2024

SI-BONE, Inc. Updates Financial Guidance for the Year 2024

SI-BONE, Inc. to Report Q3, 2024 Results on Nov 12, 2024

SI-BONE, Inc. Announces First-In-Patient Procedures with FDA Breakthrough Device for Pelvic Fracture Fixation

CEO & Director recently sold €126k worth of stock

Second quarter 2024 earnings released: US$0.22 loss per share (vs US$0.30 loss in 2Q 2023)

SI-BONE, Inc. Revises Financial Guidance for 2024

New minor risk - Share price stability

SI-BONE, Inc. to Report Q2, 2024 Results on Aug 05, 2024

New minor risk - Share price stability

Si-Bone, Inc. Increases Revenue Guidance for 2024

First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.32 loss in 1Q 2023)

Insufficient new directors

SI-BONE, Inc., Annual General Meeting, Jun 25, 2024

SI-BONE, Inc. to Report Q1, 2024 Results on May 06, 2024

New minor risk - Profitability

SI-BONE, Inc. Provides Earnings Guidance for the Year 2024

Full year 2023 earnings released: US$1.13 loss per share (vs US$1.79 loss in FY 2022)

Forecast to breakeven in 2026

CEO & Director recently sold €751k worth of stock

SI-BONE, Inc. to Report Q4, 2023 Results on Feb 26, 2024

SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application

Forecast to breakeven in 2026

SI-Bone, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Executive Chairman recently sold €130k worth of stock

SI-BONE, Inc. Increases Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$0.25 loss per share (vs US$0.41 loss in 3Q 2022)

New major risk - Revenue and earnings growth

SI-BONE, Inc. to Report Q3, 2023 Results on Nov 06, 2023

SI-BONE, Inc. Announces iFuse Bedrock Granite® Implant System Compatibility with Certain Medtronic CD Horizon® Solera 5.5/6.0 System Rods

CEO & Director recently sold €173k worth of stock

Independent Director recently sold €561k worth of stock

SI-BONE, Inc. Revises Revenue Guidance for the Year 2023

Second quarter 2023 earnings released: US$0.30 loss per share (vs US$0.54 loss in 2Q 2022)

SI-BONE, Inc. to Report Q2, 2023 Results on Aug 07, 2023

CEO & Director recently sold €206k worth of stock

SI-BONE, Inc. has completed a Follow-on Equity Offering in the amount of $83.05 million.

First quarter 2023 earnings released: US$0.32 loss per share (vs US$0.52 loss in 1Q 2022)

SI-BONE, Inc. to Report Q4, 2022 Results on Feb 27, 2023

SI-BONE, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2022

SI-BONE, Inc. Announces FDA Clearance for Expanded Rod Compatibility with the iFuse Bedrock Granite(R) Implant System

Executive Chairman recently sold €101k worth of stock

Third quarter 2022 earnings released: US$0.41 loss per share (vs US$0.48 loss in 3Q 2021)

SI-BONE, Inc. Updates Revenue Guidance for the Year 2022

SI-BONE, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Executive Chairman recently sold €135k worth of stock

SI-BONE, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Second quarter 2022 earnings released: US$0.54 loss per share (vs US$0.42 loss in 2Q 2021)

SI-BONE, Inc. to Report Q2, 2022 Results on Aug 08, 2022

SI-BONE, Inc. Announces FDA Clearance for Expanded Indication of the iFuse-TORQ® Implant System

SI-BONE, Inc. Receives FDA 510(k) Clearance for iFuse Bedrock Granite

Executive Chairman recently sold €68k worth of stock

First quarter 2022 earnings released: US$0.52 loss per share (vs US$0.37 loss in 1Q 2021)

SI-BONE, Inc. Provides Revenue Guidance for the Full Year 2022

SI-BONE, Inc., Annual General Meeting, Jun 16, 2022

SI-BONE, Inc. Announces New Technology Add-On Payment for Breakthrough Adult Spinal Deformity Treatment

SI-BONE, Inc. to Report Q1, 2022 Results on May 09, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

SI-BONE, Inc. Provides Revenue Guidance for the Full Year 2022

Executive Chairman recently sold €80k worth of stock

SI-BONE, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Executive Chairman recently sold €122k worth of stock

Third quarter 2021 earnings released: US$0.48 loss per share (vs US$0.33 loss in 3Q 2020)

Executive Chairman recently sold €120k worth of stock

Second quarter 2021 earnings released: US$0.42 loss per share (vs US$0.44 loss in 2Q 2020)

SI-BONE, Inc. Provides Earnings Guidance for the Year 2021

Executive Chairman recently sold €52k worth of stock

Si-Bone, Inc. Announces the Introduction of the Si-Bone Simulator Powered by Medability for Ifuse Surgeon Training and Education